vs
PROVIDENT FINANCIAL SERVICES INC（PFS）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
PROVIDENT FINANCIAL SERVICES INC的季度营收约是VERACYTE, INC.的1.6倍（$225.2M vs $139.1M），PROVIDENT FINANCIAL SERVICES INC净利率更高（35.3% vs 20.6%，领先14.6%），过去两年PROVIDENT FINANCIAL SERVICES INC的营收复合增速更高（17.3% vs 10.2%）
PNC金融服务集团是总部位于美国宾夕法尼亚州匹兹堡的银行控股及金融服务企业，旗下银行子公司PNC银行业务覆盖美国27个州和华盛顿特区，拥有2629家营业网点与9523台ATM机，是美国资产规模、网点数量、存款规模、ATM保有量均位居前列的大型银行机构。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
PFS vs VCYT — 直观对比
营收规模更大
PFS
是对方的1.6倍
$139.1M
净利率更高
PFS
高出14.6%
20.6%
两年增速更快
PFS
近两年复合增速
10.2%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $225.2M | $139.1M |
| 净利润 | $79.4M | $28.7M |
| 毛利率 | — | 72.7% |
| 营业利润率 | — | 16.3% |
| 净利率 | 35.3% | 20.6% |
| 营收同比 | — | 21.5% |
| 净利润同比 | 24.0% | — |
| 每股收益（稀释后） | $0.61 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PFSVCYT
| Q1 26 | $225.2M | $139.1M | ||
| Q4 25 | $225.7M | $140.6M | ||
| Q3 25 | $221.8M | $131.9M | ||
| Q2 25 | $214.2M | $130.2M | ||
| Q1 25 | $208.8M | $114.5M | ||
| Q4 24 | $205.9M | $118.6M | ||
| Q3 24 | $210.6M | $115.9M | ||
| Q2 24 | $163.8M | $114.4M |
净利润PFSVCYT
| Q1 26 | $79.4M | $28.7M | ||
| Q4 25 | — | $41.1M | ||
| Q3 25 | $71.7M | $19.1M | ||
| Q2 25 | $72.0M | $-980.0K | ||
| Q1 25 | $64.0M | $7.0M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $46.4M | $15.2M | ||
| Q2 24 | $-11.5M | $5.7M |
毛利率PFSVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% |
营业利润率PFSVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | 49.7% | 26.4% | ||
| Q3 25 | 45.8% | 17.4% | ||
| Q2 25 | 47.8% | -4.0% | ||
| Q1 25 | 44.0% | 2.5% | ||
| Q4 24 | 30.5% | 3.5% | ||
| Q3 24 | 31.0% | 10.4% | ||
| Q2 24 | -13.0% | 4.0% |
净利率PFSVCYT
| Q1 26 | 35.3% | 20.6% | ||
| Q4 25 | — | 29.3% | ||
| Q3 25 | 32.3% | 14.5% | ||
| Q2 25 | 33.6% | -0.8% | ||
| Q1 25 | 30.7% | 6.2% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | 22.0% | 13.1% | ||
| Q2 24 | -7.0% | 5.0% |
每股收益（稀释后）PFSVCYT
| Q1 26 | $0.61 | $0.35 | ||
| Q4 25 | $0.64 | $0.50 | ||
| Q3 25 | $0.55 | $0.24 | ||
| Q2 25 | $0.55 | $-0.01 | ||
| Q1 25 | $0.49 | $0.09 | ||
| Q4 24 | $0.37 | $0.07 | ||
| Q3 24 | $0.36 | $0.19 | ||
| Q2 24 | $-0.11 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $222.1M | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $1.3B |
| 总资产 | $25.2B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PFSVCYT
| Q1 26 | $222.1M | $439.1M | ||
| Q4 25 | $209.1M | $362.6M | ||
| Q3 25 | $299.2M | $315.6M | ||
| Q2 25 | $258.0M | $219.5M | ||
| Q1 25 | $234.1M | $186.1M | ||
| Q4 24 | $205.9M | $239.1M | ||
| Q3 24 | $244.0M | $274.1M | ||
| Q2 24 | $290.5M | $235.9M |
股东权益PFSVCYT
| Q1 26 | $2.9B | $1.3B | ||
| Q4 25 | $2.8B | $1.3B | ||
| Q3 25 | $2.8B | $1.3B | ||
| Q2 25 | $2.7B | $1.2B | ||
| Q1 25 | $2.7B | $1.2B | ||
| Q4 24 | $2.6B | $1.2B | ||
| Q3 24 | $2.6B | $1.2B | ||
| Q2 24 | $2.6B | $1.1B |
总资产PFSVCYT
| Q1 26 | $25.2B | $1.4B | ||
| Q4 25 | $25.0B | $1.4B | ||
| Q3 25 | $24.8B | $1.4B | ||
| Q2 25 | $24.5B | $1.3B | ||
| Q1 25 | $24.2B | $1.3B | ||
| Q4 24 | $24.1B | $1.3B | ||
| Q3 24 | $24.0B | $1.3B | ||
| Q2 24 | $24.1B | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $35.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.23× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PFSVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $442.3M | $52.6M | ||
| Q3 25 | $98.0M | $44.8M | ||
| Q2 25 | $186.8M | $33.6M | ||
| Q1 25 | $88.5M | $5.4M | ||
| Q4 24 | $426.4M | $24.5M | ||
| Q3 24 | $69.2M | $30.0M | ||
| Q2 24 | $76.5M | $29.6M |
自由现金流PFSVCYT
| Q1 26 | — | — | ||
| Q4 25 | $430.7M | $48.8M | ||
| Q3 25 | $96.7M | $42.0M | ||
| Q2 25 | $182.6M | $32.3M | ||
| Q1 25 | $87.4M | $3.5M | ||
| Q4 24 | $425.1M | $20.4M | ||
| Q3 24 | $67.9M | $27.7M | ||
| Q2 24 | $75.5M | $26.8M |
自由现金流率PFSVCYT
| Q1 26 | — | — | ||
| Q4 25 | 190.8% | 34.7% | ||
| Q3 25 | 43.6% | 31.8% | ||
| Q2 25 | 85.2% | 24.8% | ||
| Q1 25 | 41.9% | 3.1% | ||
| Q4 24 | 206.4% | 17.2% | ||
| Q3 24 | 32.2% | 23.9% | ||
| Q2 24 | 46.1% | 23.4% |
资本支出强度PFSVCYT
| Q1 26 | — | — | ||
| Q4 25 | 5.1% | 2.7% | ||
| Q3 25 | 0.6% | 2.1% | ||
| Q2 25 | 2.0% | 1.0% | ||
| Q1 25 | 0.5% | 1.6% | ||
| Q4 24 | 0.6% | 3.5% | ||
| Q3 24 | 0.6% | 1.9% | ||
| Q2 24 | 0.6% | 2.4% |
现金转化率PFSVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | 1.37× | 2.34× | ||
| Q2 25 | 2.59× | — | ||
| Q1 25 | 1.38× | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | 1.49× | 1.98× | ||
| Q2 24 | — | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PFS
| Net Interest Income | $193.7M | 86% |
| Noninterest Income | $31.5M | 14% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
